Cyprotex PLC Appointment of new Director of US Operations
September 26 2016 - 2:01AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
26 September 2016
Cyprotex PLC
("Cyprotex" or "the Company")
Cyprotex appoint new Director of US Operations
Cyprotex PLC (AIM:CRX), a specialist Contract Research
Organisation (CRO), announced today the appointment of Dr Monica
Metea as Director of US Operations. The role, which commences on
26th September 2016, will provide operational and scientific
leadership to the two Cyprotex facilities in the US at Watertown,
MA and Kalamazoo, MI.
Prior to joining Cyprotex, Dr Metea held senior roles at WIL
Research Laboratories LLC (recently acquired by Charles River
Laboratories International Inc), Covance Laboratories Inc, and most
recently Smithers Viscient where she held a Director's position. Dr
Metea has been awarded a PhD in Neuroscience from the University of
Minnesota. She is a recognised expert consultant in preclinical
electrophysiology and drug safety, and has a strong background in
safety pharmacology and toxicology.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments
on the appointment: "I am delighted to welcome such an accredited
scientist and leader to Cyprotex. Within the industries in which we
operate, the US is the largest market. It is important therefore
that we leverage this potential opportunity. We are confident that
Monica has the drive, experience and credentials to direct and grow
future business within this critical target market."
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1500 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling solutions including Cloe(R) PK, chemTarget,
chemPK(TM) and chemTox, and a range of skin, ocular and endocrine
disruption services. For more information, please visit
www.cyprotex.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABLGDCLXDBGLX
(END) Dow Jones Newswires
September 26, 2016 02:01 ET (06:01 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024